CTKB (Cytek Biosciences) Total Debt per Share: $0.21 (As of Mar. 2026)


CTKB Cytek Biosciences Inc CTKB
71 GF Score
Price $4.63
GF Value $5.83
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Cytek Biosciences Total Debt per Share?

Cytek Biosciences CTKB +0.54% 71 Total Debt per Share is $0.21 as of Mar. 2026. GuruFocus rates CTKB with a GF Score™ of 71/100 and a GF Value™ of $5.83 (Modestly Undervalued). The stock has 5 warning signs investors should review.

$0.21 (As of Mar. 2026)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Cytek Biosciences's Total Debt Per Share for the quarter that ended in Mar. 2026 was $0.21.

Cytek Biosciences Total Debt per Share Historical Data

* Premium members only.

The historical data trend for Cytek Biosciences's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cytek Biosciences Total Debt per Share Chart

Cytek Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Debt per Share
Get a 7-Day Free Trial 0.00 0.13 0.11 0.13 0.19

Cytek Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Debt per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.13 0.19 0.19 0.19 0.21
CTKB
71GF Score
Cytek Biosciences Inc CTKB
Total Debt per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cytek Biosciences Total Debt per Share Calculation

Cytek Biosciences's Total Debt Per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(14.6+9.2)/128.6
=0.18

Cytek Biosciences's Total Debt Per Share for the quarter that ended in Mar. 2026 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(13.8+13.7)/129.1
=0.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Debt per Share →
What does a Total Debt per Share of $0.21 mean?
Cytek Biosciences (CTKB) has a Total Debt per Share of $0.21 as of Mar. 2026. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Cytek Biosciences and its competitors.
Is Cytek Biosciences' Total Debt per Share too high?
Cytek Biosciences' current Total Debt per Share is $0.21. Overall, Cytek Biosciences has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cytek Biosciences' Total Debt per Share compare to CERS and NPCE?
Cytek Biosciences' Total Debt per Share of $0.21 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Debt per Share for a Medical Devices & Instruments company?
A good Total Debt per Share depends on the Medical Devices & Instruments industry context. However, Total Debt per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Debt per Share mean?
A high Total Debt per Share can signal that a stock is expensive relative to its fundamentals. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Cytek Biosciences and its competitors. Cytek Biosciences's current Total Debt per Share is $0.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cytek Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Cytek Biosciences (CTKB) is currently considered Modestly Undervalued. The stock's GF Value™ is $5.83, compared to a current price of $4.63 — trading 20.6% below its estimated fair value. The current Total Debt per Share is $0.21. Cytek Biosciences' overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Debt per Share calculated?
Total Debt per Share is calculated from a company's financial statements. For Cytek Biosciences (CTKB), the current Total Debt per Share is $0.21 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cytek Biosciences (CTKB) Overvalued in 2026?

Based on GuruFocus' analysis, Cytek Biosciences stock appears to be undervalued. The current stock price of $4.63 is trading 20.6% below its estimated GF Value™ of $5.83. GuruFocus considers Cytek Biosciences to be Modestly Undervalued.

Key valuation signals for CTKB:

  • Total Debt per Share: $0.21
  • GF Value™: $5.83 vs. price of $4.63 (20.6% below fair value)
  • GF Score™: 71/100 with 5 warning signs

No single metric tells the full story. See the CTKB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cytek Biosciences Business Description

Other Exchanges 8EQ:Germany
Address 47215 Lakeview Boulevard, Fremont, CA, USA, 94538
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its patented FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize an inventive method of light detection and distribution to a specifically selected number and type of detectors. Its FSP cell analyzers, the Cytek Aurora, Northern Lights, and Cytek Aurora Evo systems, deliver high-resolution, high-content and high-sensitivity cell analysis and address the inherent limitations of other technologies.
71GF Score

Get the complete analysis for CTKB

Total Debt per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.63
Price
$5.83
GF Value